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A(-20)C polymorphism of the angiotensinogen gene and pro- 10 years is assumed to range between 80% and 85%
gression of IgA nephropathy. from apparent onset [1]. Familial clustering of IgAN and
Background. The M235T polymorphism of the angioten- inter-individual differences in the clinical course suggestssinogen gene (AGT) is associated with an increased risk of
that genetic factors may contribute to the developmentprimary hypertension, which may then lead to progressive renal
and progression of this disease.disease. Recent studies showed that nucleotide substitution in
the 5 upstream core promoter region of AGT affects the basal Previous studies provided definitive evidence that an-
transcription rate of the gene. giotensinogen gene (AGT) variants are important in the
Methods. To evaluate the role of AGT polymorphisms in pathogenesis of cardiovascular diseases such as hyper-the progression of IgA nephropathy (IgAN), we analyzed the
tension. Changes in the 5 upstream core promoter re-association of A(-20)C and M235T polymorphisms with renal
gion of AGT, which is essential for the transcription ofprognosis in histologically-proven IgAN patients using the
Kaplan-Meier method and Cox proportional hazards regres- angiotensinogen mRNA, may cause functional differ-
sion model. ences that may contribute to pathogenesis [2]. One muta-
Results. The incidence of hypertension during the course tion in particular, an adenine-to-cytosine transition atwas associated with T235, but not with C(-20). The renal sur-
nucleotide -20 of the 5 upstream core promoter regionvival rate for 137 patients with creatinine clearance (CCr) of 70
[A(-20)C] has been shown to increase the basal promotermL/min or greater at the time of renal biopsy, and follow-up
time of two years or more was significantly lower in the patients activity of AGT by increasing the affinity of adenoviral
with C(-20) (P  0.008). The Cox proportional hazards regres- major late transcription factor (MLTF) to this region of
sion model showed an increased hazard ratio (HR) for urinary
the promoter [3].protein (more than 2 g/day) of 28.3 (95% CI, 7.3 to 109.8; P 
The existence of an association between AGT poly-0.001), hypertension at the time of renal biopsy of 4.6 (95%
CI, 1.8 to 11.9; P  0.002), and C(-20) of 3.6 (95% CI, 1.5 to morphisms and the progression of IgA nephropathy is
8.7; P  0.004). a controversial issue. Pei et al showed that patients with
Conclusion. This work provides evidence that the C(-20) the AGT 235MT and TT genotypes have a faster rate
polymorphism of AGT, a subset of T235 alleles, is associated
of deterioration in creatinine clearance (CCr) than thosewith progression of renal dysfunction in IgAN.
with the MM genotypes [4]. However, whether variations
in the core promoter region of AGT are associated with
an actuarial long-term renal prognosis in patients withImmunoglobulin A nephropathy (IgAN) is the most
IgAN is yet to be fully investigated.common glomerulonephritis among patients undergoing
renal biopsy throughout the world. It is characterized by
mesangial proliferative glomerulonephritis with pre- METHODS
dominant IgA deposits. The actuarial renal survival at Patients
Patients were recruited from Niigata University Hos-
pital (Niigata, Japan) as well as other hospitals in theKey words: mesangial proliferative glomerulosclerosis, progressive re-
nal disease, glomerulonephritis, hypertension, M235T. Niigata prefecture. The ethics committee of each insti-
tute approved the study. Informed consent was obtainedReceived for publication August 7, 2001
from all participants in the genetic studies.and in revised form February 15, 2002
Accepted for publication April 8, 2002 IgAN was diagnosed by renal biopsy as a mesangial
proliferative glomerulonephritis with predominant IgA 2002 by the International Society of Nephrology
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and C3 depositions in the mesangium. Henoch-Scho¨nlein These samples were separated by 3% agarose gel electro-
phoresis, and visualized by ethidium bromide staining.purpura and secondary IgAN as hepatic glomeruloscle-
rosis were excluded from the analysis. The M235T variant of AGT at exon two was deter-
mined as described previously [6].To analyze the renal survival rate, 137 IgAN patients
with a CCr level of 70 mL/min or greater and a follow-
Statistical analysisup time of two years or greater were studied. Patients
whose CCr value was less than 70 mL/min at the time of Pair-wise linkage disequilibrium (LD) coefficients were
the renal biopsy were excluded because there may have estimated by the maximum-likelihood method and the
been considerable differences in the onset of IgAN in extent of disequilibrium was expressed as D  D/Dmax
these patients. Patients whose follow-up time was less or D/Dmin, according to Thompson et al [7]. Haplo-
than two years also were excluded in order to eliminate type frequencies for pairs of alleles were estimated using
the influence of factors other than glomerulonephritis it- the Estimating Haplotype-Frequencies software program
self. Clinical characteristics including age, sex, duration of (ftp://linkage.rockefeller.edu/software/eh).
observation (in months), body mass index (BMI; kg/m2), Statview 5.0J software (SAS Institute, Inc., Cary, NC,
level of urinary protein excretion (g/day), serum creati- USA) was used for statistical analysis. Continuous vari-
nine (SCr; mg/dL), and CCr (mL/min) were investigated ables were expressed as mean  SD or percentage ac-
in these patients. Hypertension was defined by the use cording to clinical features. When the baseline character-
of one or more antihypertensive medications and/or a istic was continuous (age, disease duration, BMI, urinary
blood pressure greater than or equal to 140 mm Hg systolic protein, SCr, CCr), the unpaired t test and Mann-Whitney
or 90 mm Hg diastolic blood pressure. The primary end U test were used. The 2 test was used when indicated.
point was defined as the date at which SCr levels doubled The Kaplan-Meier method and the Cox proportional
after the time of diagnosis, or when patients underwent hazards regression model analyzed the time course from
their first hemodialysis. For statistical analysis, patients renal biopsy to the end point (initiation of dialysis or
with C(-20) (N  55) were compared with those without when the SCr level doubled after the time of diagnosis).
C(-20) (N  82) for age, sex, BMI, blood pressure, pro- In the Cox regression model, we tested covariates [age,
teinuria, SCr, CCr at the time of renal biopsy, and medical sex, BMI, urinary protein, the category of hypertension,
therapy. steroid therapy, and administration of angiotensin-con-
A similar analysis was performed in subgroups of the verting enzyme inhibitor (ACEI), and the gene polymor-
patients with CCr levels of 70 mL/min or greater who phism] by a stepwise backward method and several co-
were followed for more than three (N  120) or five variates were selected. The effects of these covariates
years (N  92). were expressed by a hazard ratio. A P value less than
0.05 was considered statistically significant.
DNA analysis
Genomic DNA from each patient was prepared from
RESULTSperipheral leukocytes in blood samples using an auto-
The genotype distribution in this study was not differ-matic DNA isolation system (NA-100; Kurabo, Osaka,
ent from that in Hardy-Weinberg equilibrium. The geno-Japan).
type and allele frequencies of AGT M235T and A(-20)CTo determine the A-C transition at nucleotide -20 of
did not differ from previously reported in Japanese stud-the 5 upstream region of the core promoter of the AGT
ies [5, 8–10]. Haplotype analysis showed a LD betweengene, the following primers were constructed: 5-primer,
these two alleles (LD coefficient: D, 1.00). Because the5-AGAGGTCCCAGCGTGAGTGTC-3 (nucleotides
166 to 144); 3-primer, 5-AGCCCACAGCTCAGT AGT variant at -20 was observed only in a subset of the
235T alleles, the following haplotypes were determined:TACATC-3 (nucleotides 81 to 101) [5]. Polymerase
chain reaction (PCR) was performed in a final volume T235 & C(-20); T235 & A(-20); and M235 & A(-20)
(Table 1).of 50L containing 100 ng DNA, 10 pmol of each primer,
250 mmol/L of each of the four dNTPs, 1.5 mmol/L Clinical characteristics of the patients investigated are
listed in Table 2. A comparison between patients eitherMgCl2, 50 mmol/L KCl, 10 mmol Tris-HCl at pH 8.4,
and 2 U of Taq polymerase (Takara, Shiga, Japan). The homozygous or heterozygous for C(-20) and those with-
out C(-20) showed no significant differences in age, sex,PCR conditions were as follows: 30 cycles of 94C for
30 seconds, 64C for one minute, and 72C for one mi- BMI, SCr, CCr, urinary protein excretion, blood pressure
at the time of renal biopsy, or in the percentage of casesnute. After PCR, 265-bp products including the 5 up-
stream core promoter region were obtained. Then, 8.5 treated by ACEI. The percentages of patients adminis-
tered an antihypertensive agent were not different be-L of the unpurified product was digested with 2 U of
EcoO109I (Takara) for at least three hours at 37C. tween the patients with C(-20) and those without C(-20).
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Table 1. Genotype, allele, and haplotype frequencies an increased hazard ratio (HR) for C(-20), 3.6 (95% CI,
1.5 to 8.7; P  0.004) from multivariate analysis, includ-Genotype distribution M235T A(-20)C
ing several covariates selected by stepwise backwardMM 2 AA 82
MT 41 AC 49 analysis (hypertension at the time of renal biopsy, pro-
TT 94 CC 6 teinuria more than one or two grams per day; Table 4).
Allele frequency M235T A(-20)C The HR for urinary protein more than two grams per
M 0.16 A 0.22 day (vs. 1 g/day) was extensively increased, which was
T 0.84 C 0.78 28.3 (95% CI, 7.3 to 109.8; P  0.001) from multivariate
Haplotype frequency analysis. Hypertension at the time of renal biopsy was
T235 & C(-20) 0.22 demonstrated to be a statistically significant risk factor
T235 & A(-20) 0.62 in multivariate analysis including urinary protein andM235 & A(-20) 0.16
C(-20) (HR 4.6; 95% CI, 1.8 to 11.9; P  0.002).
DISCUSSION
Glucocorticoids were administered significantly more fre- This study demonstrated that the renal survival rate
quently in patients with C(-20) than those without C(-20). was significantly lower in patients with C(-20) in Japa-
Because polymorphisms of AGT were reported to be nese patients with IgAN. The Cox proportional hazards
associated with essential hypertension in a previous regression model showed an increased hazard ratio, 3.6
study, the frequencies of genotype M235T were com- in multivariate analysis, indicating that this polymor-
pared between hypertensive and normotensive subjects phism is an independent risk factor for progression to
at the time of renal biopsy and during the observation end-stage renal failure.
period (Table 3). The frequency of TT235 was signifi- Previously, association studies of AGT A(-20)C and
cantly higher in the patients with hypertension during essential hypertension in the Japanese population were
the clinical course and significantly associated with the reported [5, 8–10]. However, to our knowledge an associ-
number of antihypertensive drugs used during the study ation of the AGT A(-20)C polymorphism with the pro-
period. To determine whether C(-20) and the haplotype gression of IgAN was not investigated. Our study clearly
including C(-20) are associated with hypertension, the demonstrates that C(-20) is an independent risk factor
frequencies of genotype A(-20)C and the haplotype for the progression of IgAN in patients whose renal
T235 & C(-20), T235 & A(-20) and M235 & A(-20) function was preserved at the time of renal biopsy. Many
were compared between hypertensive and normotensive confounding factors are known to affect the progression
subjects. C(-20) was not associated with any category of of IgAN, including immune-mediated events [11–13], he-
hypertension. The significant increase of M235 & A(-20) modynamic factors [14, 15], cell proliferation and an
in normotensive subjects was observed, which reflected increase in extracellular matrix [12, 16, 17]. In this study,
the symmetrical decrease of T235 allele; however, no systemic hypertension may play a role in the decline of
significant difference in the frequencies of the haplotype renal function in patients with AGT TT235, because the
T235 & C(-20) between hypertensive and normotensive TT235 was significantly associated not only with hyper-
subjects was observed in both categories. tension during the clinical course, but also with the renal
To examine the effect of A(-20)C polymorphism on prognosis. These observations were assumed to reflect
disease progression, we compared the survival rate from the influence of A(-6), which has been known to increase
renal biopsy to the end point in those patients with CCr the level of transcription of angiotensinogen, because
level of 70 mL/min or greater at renal biopsy and a A(-6)G and M235T polymorphism of AGT are in com-
follow-up time of two years or more. The renal survival plete LD [18, 19]. In contrast and unexpectedly, C(-20)
rate in patients with C(-20) was significantly less (2  was significantly associated with renal prognosis inde-
7.0, P  0.008) than in patients without C(-20) (Fig. 1). pendently of hypertension. Although the exact mecha-
Moreover, in patients with a CCr level of 70 mL/min or nism that explains these dissociated results on A(-20)C
greater at renal biopsy and follow-up time of more than and M235T polymorphisms remained unclear, these re-
three years (N  120; mean observed periods, 116.4 sults suggest that the transcriptional regulation of AGT
months) or five years (N  92; mean observed periods, in the renal tissue is distinct from the systemic circulation.
137.5 months), the renal survival rate was significantly It has been reported that angiotensin II in renal interstitial
lower in patients with C(-20) (P  0.02 at 3 years and fluids are much higher than plasma levels, suggesting the
P  0.04 at 5 years). The renal survival rate in TT235 compartmentalization and independent regulation of renal
patients (N  43) also was significantly lower than in angiotensin II [20]. Furthermore, recent haplotype studies
MM/MT235 patients (N  94; P  0.02; Fig. 2). demonstrated that LD between M235T and A(-20)C was
not more complete than M235T and A(-6)G [18, 21],The Cox proportional hazards regression model showed
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Table 2. Clinical characteristics at the time of renal biopsy
All patients (N  137) AGT AA(-20) (N  82) AGT AC/CC(-20) (N  55)
Observed periods months 105.768.3 104.669.4 107.267.1
Background 1st renal biopsy
Age years 34.912.4 35.812.8 33.511.7
Male % 45.3 43.9 47.3
BMI kg/m2 22.52.8 22.93.0 22.02.4
Uprot g/day 1.21.1 1.10.7 1.41.4
SCr mg/dL 0.80.2 0.80.2 0.80.2
CCr mL/min 104.623.5 106.624.8 101.621.2
Blood pressure mm Hg
Systolic 125.816.9 126.318.0 125.115.1
Diastolic 75.612.6 76.413.0 74.412.0
Treatment during the course
Glucocorticoid % 24.3 16.0 36.4a
Antihypertensive drugs % 53.3 47.6 61.8
ACEI % 40.1 39.0 41.8
Abbreviations are: BMI, body mass index; Uprot, urinary protein; SCr, serum creatinine; CCr, creatinine clearance; ACEI, angiotensin-converting enzyme inhibitor.
aP  0.05 vs. AGT AA(-20) patients
Table 3. Genotype and haplotype frequencies in hypertensive and normotensive subjects
At the renal biopsy During the course Number of anti-HT drugs
Genotype HT % NT % P HT % NT % P meanSD P
MM/MT235 6.6 24.8 12.4 19.0 0.71.1
TT235 25.5 43.1 0.08 47.4 21.2 0.001 1.21.3 0.003
AA(-20) 19.7 40.1 32.8 27.0 1.01.3
AC/CC(-20) 12.4 27.7 0.85 27.0 13.1 0.16 1.11.2 0.36
At the renal biopsy During the course
Haplotype HT % NT % P HT % NT % P
T235 & C(-20) 21.6 22.6 0.49 25.0 18.0 0.12
T235 & A(-20) 69.3 58.1 0.048 64.6 57.3 0.14
M235 & A(-20) 9.1 19.5 0.02 10.4 24.5 0.002
Abbreviations are: HT, hypertensives; NT, normotensives; P, P value.
Fig. 2. AGT M235T and the renal survival rate in patients with IgAN.Fig. 1. AGT A(-20)C and the renal survival rate in patients with IgAN.
The renal survival rate in patients with MM/MT235 (dotted line; N The renal survival rate in patients with C(-20) (N  55) was less than
94) was less than that in patients with TT235 (solid line; N  43). Log-that in patients without C(-20) (N  82). Symbols are: (dotted line)
rank test P  0.02.AA(-20); (solid line) AC/CC(-20). Log-rank test, P  0.008.
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Table 4. Cox proportional hazards regression model the time of renal biopsy was more than 70 mL/min.
Histopathological analysis of the patients who reachedVariable P value HR 95% CI
end points within several years revealed severe expan-Uprot
	1 g/day, 2g/day 0.01 5.4 1.5 to 20.4 sion of mesangial matrix, tuft adhesion, and crescent
	2 g/day 0.001 28.3 7.3 to 109.8 formation. However, the mean time to the end points
HT at renal biopsy 0.002 4.6 1.8 to 11.9
in our study was nearly 10 years, and a substantial pro-AGT C(-20) 0.004 3.6 1.5 to 8.7
portion of the patients had stable or slowly decliningAbbreviations are: Uprot, urinary protein; HT, hypertension; HR, hazard ratio;
CI, confidence interval. renal function during the follow-up period. D’Amico et
al’s study found that the speed of progression of end-
stage renal failure in IgAN patients was quite variable
[25]. In fact, there was a large inter-individual difference
although C(-20) is a subset of T235. There is a possibility in the time course to reach the end point, which was the
that the A(-20)C polymorphism may be chiefly related to very point we investigated here as the genetic back-
the local activation of renin-angiotensin system through ground. We employed a time-to-event analysis because
a different transcriptional regulation, leading to renal it is suggested that, in a study including patients with
dysfunction, whereas the M235T polymorphism may be stable renal function, an analysis of the time-to-event
implicated with renal dysfunction through systemic hy- approach is favored over an analysis of mean slope of
pertension. Further study is necessary to explore the renal function [26].
molecular mechanism of transcriptional regulation of Our study could not provide evidence that the AGT
AGT in the kidney under both physiological and patho- C(-20) influenced the therapeutic effect of angiotensin
logical conditions. II blockade by ACEI. In this respect, further investiga-
Several earlier studies have analyzed an association tion with a long-term prospective observation of a large
of T235 variants of AGT with the progression of IgAN. number of cases is necessary. However, our study sug-
Pei et al showed that patients with MT and TT genotypes gests that genotyping of AGT at -20 and precise clinico-
had a faster rate of deterioration of renal function than pathological assessments can lead to more accurate esti-
those with MM genotypes [4]. Because a large proportion mations of the prognosis, and to more proper and active
of patients in their study were treated with antihyperten- usage of ACEI or ARB in patients with IgAN.
sive drugs (56 to 82%) and renal function in patients
with MT or TT was moderately impaired, the effects of ACKNOWLEDGMENTS
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